Armata Pharmaceuticals, Inc. Logo

Armata Pharmaceuticals, Inc.

ARMP

(0.8)
Stock Price

1,87 USD

-70.89% ROA

89.12% ROE

-1.25x PER

Market Cap.

83.582.961,00 USD

-317% DER

0% Yield

-1658.5% NPM

Armata Pharmaceuticals, Inc. Stock Analysis

Armata Pharmaceuticals, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Armata Pharmaceuticals, Inc. Fundamental Stock Analysis
# Analysis Rating
1 Assets Growth

Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity.

2 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

3 ROE

The stock's ROE indicates a negative return (-130.1%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-45.83%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 PBV

The stock's elevated P/BV ratio (4.18x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

6 DER

The company has a high debt to equity ratio (281%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

7 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Armata Pharmaceuticals, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Armata Pharmaceuticals, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Buy

Armata Pharmaceuticals, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Armata Pharmaceuticals, Inc. Revenue
Year Revenue Growth
1993 100.000
1994 400.000 75%
1995 100.000 -300%
1996 2.300.000 95.65%
1997 900.000 -155.56%
1998 7.200.000 87.5%
1999 6.800.000 -5.88%
2000 11.402.700 40.37%
2001 18.880.000 39.6%
2002 19.333.000 2.34%
2003 14.073.000 -37.38%
2004 9.652.000 -45.8%
2005 6.874.000 -40.41%
2006 9.864.000 30.31%
2007 10.332.000 4.53%
2008 8.718.000 -18.51%
2012 664.000 -1212.95%
2013 325.000 -104.31%
2014 409.000 20.54%
2015 475.000 13.89%
2016 260.000 -82.69%
2017 115.000 -126.09%
2018 0 0%
2019 0 0%
2020 823.000 100%
2021 4.474.000 81.6%
2022 5.508.000 18.77%
2023 0 0%
2023 4.529.000 100%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Armata Pharmaceuticals, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1993 0
1994 6.800.000 100%
1995 8.200.000 17.07%
1996 11.500.000 28.7%
1997 13.000.000 11.54%
1998 13.300.000 2.26%
1999 14.300.000 6.99%
2000 19.311.790 25.95%
2001 31.546.000 38.78%
2002 31.315.000 -0.74%
2003 17.197.000 -82.1%
2004 17.288.000 0.53%
2005 18.199.000 5.01%
2006 14.482.000 -25.67%
2007 17.709.000 18.22%
2008 15.183.000 -16.64%
2012 1.480.000 -925.88%
2013 6.502.000 77.24%
2014 5.805.000 -12.01%
2015 3.992.000 -45.42%
2016 5.678.000 29.69%
2017 2.881.000 -97.08%
2018 4.892.000 41.11%
2019 9.824.000 50.2%
2020 14.444.000 31.99%
2021 20.015.000 27.83%
2022 35.017.000 42.84%
2023 31.912.000 -9.73%
2023 33.770.000 5.5%
2024 33.900.000 0.38%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Armata Pharmaceuticals, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1993 0
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 6.203.000 100%
2002 8.067.000.000.000 100%
2003 5.490.000 -146939790.71%
2004 6.650.000 17.44%
2005 6.313.000 -5.34%
2006 6.382.000 1.08%
2007 7.029.000 9.2%
2008 5.822.000 -20.73%
2012 3.208.000 -81.48%
2013 8.809.000 63.58%
2014 6.850.000 -28.6%
2015 6.421.000 -6.68%
2016 8.413.000 23.68%
2017 7.590.000 -10.84%
2018 5.702.000 -33.11%
2019 9.265.000 38.46%
2020 7.966.000 -16.31%
2021 8.281.000 3.8%
2022 7.437.000 -11.35%
2023 14.332.000 48.11%
2023 11.649.000 -23.03%
2024 13.756.000 15.32%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Armata Pharmaceuticals, Inc. EBITDA
Year EBITDA Growth
1993 -5.400.000
1994 -7.000.000 22.86%
1995 -9.800.000 28.57%
1996 3.300.000 396.97%
1997 -14.400.000 122.92%
1998 -8.200.000 -75.61%
1999 -6.700.000 -22.39%
2000 16.563.788 140.45%
2001 -21.798.000 175.99%
2002 -14.868.000 -46.61%
2003 -1.187.000 -1152.57%
2004 -13.502.000 91.21%
2005 -15.271.000 11.58%
2006 -11.424.000 -33.67%
2007 -11.656.000 1.99%
2008 -3.059.000 -281.04%
2012 -4.036.000 24.21%
2013 25.658.000 115.73%
2014 -51.171.000 150.14%
2015 -19.535.000 -161.95%
2016 -8.453.000 -131.1%
2017 -6.198.000 -36.38%
2018 -8.361.000 25.87%
2019 -18.192.000 54.04%
2020 -20.439.000 10.99%
2021 -22.648.000 9.75%
2022 -36.054.000 37.18%
2023 -103.604.000 65.2%
2023 -39.918.000 -159.54%
2024 -46.396.000 13.96%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Armata Pharmaceuticals, Inc. Gross Profit
Year Gross Profit Growth
1993 500.000
1994 1.700.000 70.59%
1995 1.500.000 -13.33%
1996 4.200.000 64.29%
1997 2.500.000 -68%
1998 8.800.000 71.59%
1999 8.400.000 -4.76%
2000 13.177.374 36.25%
2001 18.880.000 30.2%
2002 19.333.000 2.34%
2003 14.073.000 -37.38%
2004 9.652.000 -45.8%
2005 6.874.000 -40.41%
2006 9.864.000 30.31%
2007 10.332.000 4.53%
2008 8.718.000 -18.51%
2012 664.000 -1212.95%
2013 325.000 -104.31%
2014 409.000 20.54%
2015 475.000 13.89%
2016 -109.000 535.78%
2017 -259.000 57.92%
2018 -1.351.000 80.83%
2019 -1.351.000 0%
2020 -13.621.000 90.08%
2021 -15.541.000 12.35%
2022 4.616.000 436.68%
2023 0 0%
2023 -29.241.000 100%
2024 -1.260.000 -2220.71%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Armata Pharmaceuticals, Inc. Net Profit
Year Net Profit Growth
1993 -5.100.000
1994 -8.400.000 39.29%
1995 -9.900.000 15.15%
1996 -26.000.000 61.92%
1997 -14.200.000 -83.1%
1998 -8.700.000 -63.22%
1999 -26.700.000 67.42%
2000 -47.655.691 43.97%
2001 -27.170.000 -75.4%
2002 -23.767.000 -14.32%
2003 -14.833.000 -60.23%
2004 -14.257.000 -4.04%
2005 -19.198.000 25.74%
2006 -33.990.000 43.52%
2007 -16.127.000 -110.76%
2008 -20.720.000 22.17%
2012 -1.110.000 -1766.67%
2013 -58.411.000 98.1%
2014 23.109.000 352.76%
2015 -516.000 4578.49%
2016 -18.838.000 97.26%
2017 -12.838.000 -46.74%
2018 -12.110.000 -6.01%
2019 -19.025.000 36.35%
2020 -22.815.000 16.61%
2021 -23.219.000 1.74%
2022 -36.888.000 37.06%
2023 -124.644.000 70.41%
2023 -69.045.000 -80.53%
2024 35.944.000 292.09%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Armata Pharmaceuticals, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1993 -196
1994 -7.000 97.21%
1995 -4.701 -48.94%
1996 -7.924 40.69%
1997 -3.516 -125.43%
1998 -1.633 -115.25%
1999 -4.150 60.64%
2000 -6.312 34.27%
2001 -3.093 -104.14%
2002 -2.597 -19.11%
2003 -1.290 -101.24%
2004 -12.561 89.73%
2005 -15.697 19.98%
2006 -24.313 35.44%
2007 -6.842 -255.35%
2008 -7.270 5.89%
2012 -162 -4415.53%
2013 -4.040 96.01%
2014 589 785.91%
2015 -13 4630.77%
2016 -268 95.15%
2017 -28 -857.14%
2018 -9 -250%
2019 -2 -300%
2020 -1 -100%
2021 -1 0%
2022 -1 100%
2023 -3 66.67%
2023 -2 -200%
2024 1 200%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Armata Pharmaceuticals, Inc. Free Cashflow
Year Free Cashflow Growth
1993 -8.900.000
1994 -8.100.000 -9.88%
1995 -9.800.000 17.35%
1996 -11.900.000 17.65%
1997 -13.200.000 9.85%
1998 -6.000.000 -120%
1999 -12.500.000 52%
2000 -3.402.523 -267.37%
2001 -27.954.000 87.83%
2002 -20.659.000 -35.31%
2003 -11.546.000 -78.93%
2004 -15.931.000 27.52%
2005 -17.060.000 6.62%
2006 -11.717.000 -45.6%
2007 -14.436.000 18.83%
2008 -11.043.000 -30.73%
2012 -4.334.000 -154.8%
2013 -7.550.000 42.6%
2014 -13.774.000 45.19%
2015 -9.991.000 -37.86%
2016 -10.868.000 8.07%
2017 -9.250.000 -17.49%
2018 -9.426.000 1.87%
2019 -15.713.000 40.01%
2020 -19.094.000 17.71%
2021 -24.879.000 23.25%
2022 -34.692.000 28.29%
2023 -13.199.000 -162.84%
2023 -55.567.000 76.25%
2024 -11.543.000 -381.39%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Armata Pharmaceuticals, Inc. Operating Cashflow
Year Operating Cashflow Growth
1993 -4.400.000
1994 -7.200.000 38.89%
1995 -8.500.000 15.29%
1996 -10.400.000 18.27%
1997 -12.500.000 16.8%
1998 -5.800.000 -115.52%
1999 -10.600.000 45.28%
2000 -605.544 -1650.49%
2001 -23.543.000 97.43%
2002 -20.096.000 -17.15%
2003 -11.230.000 -78.95%
2004 -15.523.000 27.66%
2005 -16.391.000 5.3%
2006 -11.636.000 -40.86%
2007 -13.882.000 16.18%
2008 -10.305.000 -34.71%
2012 -4.281.000 -140.71%
2013 -7.448.000 42.52%
2014 -12.572.000 40.76%
2015 -9.781.000 -28.53%
2016 -10.589.000 7.63%
2017 -9.192.000 -15.2%
2018 -9.382.000 2.03%
2019 -15.582.000 39.79%
2020 -18.270.000 14.71%
2021 -23.575.000 22.5%
2022 -32.481.000 27.42%
2023 -9.687.000 -235.31%
2023 -47.423.000 79.57%
2024 -10.177.000 -365.98%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Armata Pharmaceuticals, Inc. Capital Expenditure
Year Capital Expenditure Growth
1993 4.500.000
1994 900.000 -400%
1995 1.300.000 30.77%
1996 1.500.000 13.33%
1997 700.000 -114.29%
1998 200.000 -250%
1999 1.900.000 89.47%
2000 2.796.979 32.07%
2001 4.411.000 36.59%
2002 563.000 -683.48%
2003 316.000 -78.16%
2004 408.000 22.55%
2005 669.000 39.01%
2006 81.000 -725.93%
2007 554.000 85.38%
2008 738.000 24.93%
2012 53.000 -1292.45%
2013 102.000 48.04%
2014 1.202.000 91.51%
2015 210.000 -472.38%
2016 279.000 24.73%
2017 58.000 -381.03%
2018 44.000 -31.82%
2019 131.000 66.41%
2020 824.000 84.1%
2021 1.304.000 36.81%
2022 2.211.000 41.02%
2023 3.512.000 37.04%
2023 8.144.000 56.88%
2024 1.366.000 -496.19%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Armata Pharmaceuticals, Inc. Equity
Year Equity Growth
1993 10.200.000
1994 13.200.000 22.73%
1995 15.800.000 16.46%
1996 19.500.000 18.97%
1997 5.600.000 -248.21%
1998 12.000.000 53.33%
1999 7.000.000 -71.43%
2000 63.431.597 88.96%
2001 37.401.000 -69.6%
2002 6.646.000 -462.76%
2003 34.229.000 80.58%
2004 49.762.000 31.21%
2005 30.571.000 -62.78%
2006 5.367.000 -469.61%
2007 16.240.000 66.95%
2008 -3.772.000 530.54%
2012 12.943.000 129.14%
2013 -14.221.000 191.01%
2014 3.437.000 513.76%
2015 12.714.000 72.97%
2016 9.723.000 -30.76%
2017 7.731.000 -25.77%
2018 8.474.000 8.77%
2019 14.593.000 41.93%
2020 18.857.000 22.61%
2021 25.397.000 25.75%
2022 36.080.000 29.61%
2023 -32.064.999 212.52%
2023 -12.386.000 -158.88%
2024 -46.101.000 73.13%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Armata Pharmaceuticals, Inc. Assets
Year Assets Growth
1993 12.100.000
1994 17.000.000 28.82%
1995 20.000.000 15%
1996 25.100.000 20.32%
1997 9.800.000 -156.12%
1998 16.200.000 39.51%
1999 13.700.000 -18.25%
2000 87.974.042 84.43%
2001 71.038.000 -23.84%
2002 52.712.000 -34.77%
2003 57.672.000 8.6%
2004 69.965.000 17.57%
2005 48.798.000 -43.38%
2006 17.467.000 -179.37%
2007 28.474.000 38.66%
2008 7.150.000 -298.24%
2012 22.071.000 67.6%
2013 37.947.000 41.84%
2014 28.617.000 -32.6%
2015 31.493.000 9.13%
2016 18.195.000 -73.09%
2017 11.138.000 -63.36%
2018 11.887.000 6.3%
2019 25.451.000 53.29%
2020 39.516.000 35.59%
2021 69.768.000 43.36%
2022 95.834.000 27.2%
2023 109.964.000 12.85%
2023 112.761.000 2.48%
2024 108.313.000 -4.11%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Armata Pharmaceuticals, Inc. Liabilities
Year Liabilities Growth
1993 1.900.000
1994 3.800.000 50%
1995 4.200.000 9.52%
1996 5.600.000 25%
1997 4.200.000 -33.33%
1998 4.200.000 0%
1999 6.700.000 37.31%
2000 24.542.445 72.7%
2001 33.637.000 27.04%
2002 46.066.000 26.98%
2003 23.443.000 -96.5%
2004 20.203.000 -16.04%
2005 18.227.000 -10.84%
2006 12.100.000 -50.64%
2007 12.234.000 1.1%
2008 10.922.000 -12.01%
2012 9.128.000 -19.65%
2013 52.168.000 82.5%
2014 25.180.000 -107.18%
2015 18.779.000 -34.09%
2016 8.472.000 -121.66%
2017 3.407.000 -148.66%
2018 3.413.000 0.18%
2019 10.858.000 68.57%
2020 20.659.000 47.44%
2021 44.371.000 53.44%
2022 59.754.000 25.74%
2023 142.029.000 57.93%
2023 125.147.000 -13.49%
2024 154.414.000 18.95%

Armata Pharmaceuticals, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.1
Net Income per Share
-1.85
Price to Earning Ratio
-1.25x
Price To Sales Ratio
22.47x
POCF Ratio
-2.17
PFCF Ratio
-1.81
Price to Book Ratio
-1.81
EV to Sales
54.67
EV Over EBITDA
-3.59
EV to Operating CashFlow
-5.27
EV to FreeCashFlow
-4.41
Earnings Yield
-0.8
FreeCashFlow Yield
-0.55
Market Cap
0,08 Bil.
Enterprise Value
0,20 Bil.
Graham Number
7.29
Graham NetNet
-3.51

Income Statement Metrics

Net Income per Share
-1.85
Income Quality
0.58
ROE
1.82
Return On Assets
-0.42
Return On Capital Employed
2.08
Net Income per EBT
1
EBT Per Ebit
1
Ebit per Revenue
-16.63
Effective Tax Rate
-0.44

Margins

Sales, General, & Administrative to Revenue
3.6
Research & Developement to Revenue
8.71
Stock Based Compensation to Revenue
0.45
Gross Profit Margin
0.63
Operating Profit Margin
-16.63
Pretax Profit Margin
-16.59
Net Profit Margin
-16.59

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-1.07
Free CashFlow per Share
-1.27
Capex to Operating CashFlow
-0.2
Capex to Revenue
2.02
Capex to Depreciation
6.57
Return on Invested Capital
-0.44
Return on Tangible Assets
-0.71
Days Sales Outstanding
121.9
Days Payables Outstanding
555.14
Days of Inventory on Hand
0
Receivables Turnover
2.99
Payables Turnover
0.66
Inventory Turnover
0
Capex per Share
0.21

Balance Sheet

Cash per Share
0,73
Book Value per Share
-1,28
Tangible Book Value per Share
-1.66
Shareholders Equity per Share
-1.28
Interest Debt per Share
4.24
Debt to Equity
-3.17
Debt to Assets
1.35
Net Debt to EBITDA
-2.11
Current Ratio
0.25
Tangible Asset Value
-0,06 Bil.
Net Current Asset Value
-0,12 Bil.
Invested Capital
-21387000
Working Capital
-0,09 Bil.
Intangibles to Total Assets
0.13
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
-856999.5
Debt to Market Cap
1.75

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Armata Pharmaceuticals, Inc. Dividends
Year Dividends Growth

Armata Pharmaceuticals, Inc. Profile

About Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

CEO
Dr. Deborah L. Birx M.D.
Employee
66
Address
4503 Glencoe Avenue
Marina del Rey, 90292

Armata Pharmaceuticals, Inc. Executives & BODs

Armata Pharmaceuticals, Inc. Executives & BODs
# Name Age
1 Dr. Pierre Kyme Ph.D.
Chief Business Officer
70
2 Mr. David House
Senior Vice President of Finance & Principal Financial Officer
70
3 Mr. Peter Hubbard
Vice President of Operations
70
4 Dr. Mina Pastagia M.D., MS
Chief Medical Officer
70
5 Dr. Deborah L. Birx M.D.
Chief Executive Officer & Director
70

Armata Pharmaceuticals, Inc. Competitors